The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / November / Clearing Glaucoma's Cellular Clutter
Glaucoma Neuro-ophthalmology News

Clearing Glaucoma's Cellular Clutter

Pharmacologically restoring mitochondrial clearance for impaired autophagy could offer new neuroprotection route

11/17/2026 2 min read

Share

  • Full Article
  • Summary
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll

Clinical Scorecard: Clearing Glaucoma's Cellular Clutter

At a Glance

CategoryDetail
ConditionGlaucoma-associated retinal ganglion cell and optic nerve degeneration
Key MechanismsPreclinical findings link impaired autophagy and mitophagy to abnormal mitochondrial accumulation, oxidative DNA damage, and retinal ganglion cell dysfunction and loss.
Target PopulationThe research used mouse models of glaucoma and ex vivo human retinal explants; it does not establish a treatment for patients.
Care SettingPreclinical research using animal glaucoma models and ex vivo human retinal tissue.

Key Highlights

  • In mouse glaucoma models, sustained intraocular pressure elevation was associated with structurally abnormal mitochondria in retinal ganglion cells and optic nerve axons.
  • Mitophagy was reduced after five weeks of ocular hypertension, before detectable retinal ganglion cell loss and axonal degeneration, and remained impaired after degeneration was established.
  • Six weeks after RGC-specific disruption of Atg5, eyes showed mitochondrial accumulation, oxidative DNA damage, impaired function, approximately 39% retinal ganglion cell loss, and around 59% loss of healthy optic nerve axons.
  • Intravitreal Torin 2 increased mitophagy and preserved retinal ganglion cell function in a glucocorticoid-induced mouse model without altering intraocular pressure.
  • In ex vivo human retinal explants cultured under neurotrophic factor-deprived conditions, Torin 2 increased retinal ganglion cell survival by approximately 49.7%; the findings remain preclinical.

Guideline-Based Recommendations

Diagnosis

    Management

    • The study does not provide clinical treatment recommendations; lowering intraocular pressure remains the cornerstone of glaucoma treatment, as stated in the article.
    • Torin 2 was studied as an intravitreal intervention in preclinical models and is not established here as a clinical glaucoma treatment.

    Monitoring & Follow-up

      Risks

      • The authors note that broad mTOR inhibition by Torin 2 may complicate translation.
      • In the myocilin mouse model, some neuroprotection may have resulted from an accompanying reduction in intraocular pressure.

      Patient & Prescribing Data

      No patient treatment population was studied; human tissue was examined ex vivo.

      Intravitreal Torin 2 increased mitophagy and preserved retinal ganglion cell function in a mouse model without changing intraocular pressure. The article describes the work as preclinical and notes that more selective autophagy or mitophagy modulators require further study.

      Clinical Best Practices

      • Interpret the findings as preclinical evidence, not as a basis for prescribing Torin 2 to patients.
      • Distinguish the glucocorticoid-induced mouse model, the myocilin mouse model, and the ex vivo human retinal explant findings when considering the reported effects.
      • The authors identify more selective autophagy or mitophagy modulators and pathway-specific interventions as priorities for future research.

      Related Resources & Content

      • Maddineni P, et al. Study published in Molecular Neurodegeneration.

      This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

      Related Content

      Newsletters

      Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

      Newsletter Signup Image

      False

      Advertisement

      False

      Advertisement

      Explore More in Ophthalmology

      Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

      False

      Advertisement
      The Ophthalmologist
      Subscribe

      About

      • About Us
      • Work at Conexiant Europe
      • Terms and Conditions
      • Privacy Policy
      • Your Privacy Choices
      • Advertise With Us
      • Contact Us

      Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

      Affiliations:

      Specialties:

      Areas of Expertise:

      Contributions:

      Disclaimer

      The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: